Navigation Links
Helix BioPharma Announces Q2 2009 Financial Results
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second quarter of fiscal 2009, ended January 31, 2009.

RECENT HIGHLIGHTS

  • Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission which became effective on March 12, 2009

  • Helix received regulatory approval to commence a small European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials

  • Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

Results from Operations

Three and six month periods ended January 31, 2009 compared to the same periods in the previous year

Loss for the period

The Company recorded a loss of $4,252,000 and $6,573,000, respectively, for the three and six month periods ended January 31, 2009, for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a loss of $1,526,000 and $3,170,000, respectively, for a loss per common share of $0.04 and $0.08, respectively.

Revenues

Total revenues for the three month period ended January 31, 2009 totaled $863,000 (2008 - $791,000), resulting in an increase of $72,000 or 9.1%. Total revenues, for the six month period ended January 31, 2009 totaled $1,982,000 (2008 - $1,676,000), resulting in an increase of $306,000 or 18.3%.

Product Revenue

Product revenue totaled $740,000 and $1,661,000 respectively for the three and six month periods ended January 31, 2009 and represent an increase of $88,000 (13.5%
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... Bridgewater, NJ (PRWEB) May 21, 2015 ... and a method for diagnostic or therapeutic imaging within ... the apparatus uses an endoscope having a low cost, ... original USPTO filing date was October 18, 2013 and ... The technology enables the physician to customize the ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... , BEIJING , June 1 ... in the development, assembly, marketing and,sale of medical products in China ... China of a sophisticated anesthesia product manufactured,by Penlon, a UK firm ... , , ...
... June 1 Oncimmune LLC, maker of ... in risk assessment and the early detection of lung ... and economic benefits of a standardized and reproducible autoantibody ... for lung cancer patients. Currently, lung cancer is responsible ...
... ... series into its curriculum. The online drug safety training courses from BioSoteria will ... and PhD students, postdoctoral fellows, and residents via the University of Maryland’s Blackboard system. ... Baltimore, ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 2Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 3Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 5Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 6Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 7University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... Singapore Immunology Network (SIgN) have discovered a new defense ... The team,s discovery of how a novel protein unexpectedly ... also be used to get rid of tumour cells. ... Basel, Switzerland, published in July 2013 in Nature ...
... -- Clearly Innovative Home and Office Products, a company that ... and high quality products including glass chair mats , ... the Midwest. (Photo: http://photos.prnewswire.com/prnh/20130909/MN76072 ) ... it has worked hard to develop and market products that ...
... Scientists have developed a strain of the Middle East respiratory ... against the disease, according to a study to be published ... American Society for Microbiology. The mutant MERS virus, rMERS-CoV-ΔE, has ... of infecting a cell and replicating its genetic material, but ...
Cached Biology News:Novel mechanism discovered in first line of immune defense 2Chair Mats of Glass Company Clearly Innovative Announces the Launch of 20 New Dealers in the Midwest 2Scientists engineer strain of MERS coronavirus for use in a vaccine 2Scientists engineer strain of MERS coronavirus for use in a vaccine 3
... High Five cells (BTI-TN-5B1-4) derived ... have been shown to be capable ... secreted recombinant proteins compared to other ... the following features:- -Rapid doubling time as ...
... Flipper® Racks are ideal for storage and ... These polypropylene racks withstand extreme temperatures, making ... They may also be autoclaved for use ... one side accommodates 0.5ml microcentrifuge tubes, the ...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
... consists of universal lysis buffer, PCR mix, ... 100 25 l volume PCR reactions. This ... negative or positive rod and coccus bacteria, ... Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and etc. ...
Biology Products: